Navigation Links
Kibow Biotech Achieves Major Victory with India's IPAB Decision to Uphold 2009 Product Patent

NEWTOWN SQUARE, Pa., Dec. 2, 2013 /PRNewswire/ -- The landmark decision by India's top IP body, the Intellectual Property Appellate Board (IPAB), to uphold Kibow Biotech's key product patent No: 224100 granted in the year 2009 by the government of India is a major victory for a small biotech company based in Pennsylvania. 

This product patent entitled "Compositions for Augmenting Kidney Function" is a probiotic dietary supplement developed over a ten-year period with extensive R&D and clinical validation. The innovative product which sells as Renadyl™ (previously sold as Kibow® Biotics in USA and Canada only) received wide acclaim around the world including from top medical professionals, scientists and the company's distinguished Scientific Advisory Board (SAB) members (   

The revocation petition against two of Kibow's patents was filed by LaRenon Health Care, an Indian pharmaceutical firm. Kibow had sued LaRenon for infringement before the Madras High Court, alleging infringement of its patents. While this suit was dismissed for procedural irregularities, La Renon filed revocations before the IPAB challenging both the product patent (Patent No: 224100) and the Process Patent (No.205478) covering a novel method of augmenting kidney function.

While the IPAB, via an order of the Vice Chairman Hon'ble S. Usha and Technical Member (Patents) Hon'ble D.P.S Parmar, invalidated the weaker process patent, it upheld the product patent. When compared to a process patent, a product patent is infinitely more valuable as it permits the patentee to prevent third parties such as LaRenon from making a copy of the product, irrespective of the process that they use to arrive at the product.

In particular, the judges agreed with the contention of Kibow that "the invention covers a new and inventive composition comprising at least one probiotics bacteria of a certain kind, in a certain composition and along with other additives (such as vitamins, etc.) that confer synergistic impact, enabling the augmentation of kidney function". The company's management and its research and development team are fully convinced and believe that "by no stretch of imagination can this unique composition be labeled as mere admixture."

Patents covering the product/process formulation on the probiotic dietary food supplement formulation have already been obtained in Australia, Canada, China, Japan, and Korea, and are pending in the European Union. Kibow Biotech is represented in India by a leading Delhi-based IP law firm, Obhan and Associates,   

About Kibow Biotech:  Founded in Oct 1, 1997 in Philadelphia, Kibow Biotech specializes in research, development and commercialization of probiotic dietary supplements adhering to US FDA and FTC regulations. The Company's primary mission is to offer affordable, readily available and easily administered dietary supplements in support of kidney health and other healthcare applications. The Company's flagship product, Renadyl™, is currently marketed in the U.S. and Canada, and will progressively be made available worldwide, according to individual countries' governmental rules and regulatory authorities.

For further information, contact:
Natarajan Ranganathan, PhD
Managing Director 
1 (610) 353-5130

Read more news from Kibow Biotech

SOURCE Kibow Biotech
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Future of Pre- and Probiotics to be Discussed by Kibow Biotech Founder During SupplySide MarketPlace 2013 Global Expo & Conference
2. GenWay Biotech Launches New Cardiovascular Diagnostic Blood Test at American Heart Association Scientific Sessions 2011
3. Puma Biotechnology Announces Completion of Private Placement
4. Animal Biotechnology - Technologies, Markets and Companies
5. AtheroNova and Maxwell Biotech Group Ratify Agreement to Develop New Atherosclerosis Drug
6. The European Union Signs Grant Contract to Fund a 2 Million Euro Biotechnology Research Project Led by Hadassah College Jerusalem
7. Janssen Biotech, Inc. Announces Collaborative Development and Worldwide License Agreement for Investigational Anti-Cancer Drug, PCI-32765
8. Puma Biotechnology Announces Positive PB272 (Neratinib) Phase II Data at CTRC-AACR San Antonio Breast Cancer Symposium
9. Metamark Genetics Signs Collaboration Agreement on Novel Therapeutic Targets with Janssen Biotech
10. SuperNova Diagnostics® to Present at Biotech Showcase™ 2012 During JP Morgan Healthcare Conference January 9 - 12
11. Saladax Biomedical, Inc. to Present at Biotech Showcase™ 2012
Post Your Comments:
(Date:11/25/2015)... 2015 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ:  AEZS; TSX: ... prospects remain fundamentally strong and highlights the following ... received DSMB recommendation to continue the ZoptEC Phase ... the final interim efficacy and safety data ... men with heavily pretreated castration- and Taxane-resistant prostate ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... featured on AngelList early in their initial angel funding process. Now, they are ... individuals looking to make early stage investments in the microbiome space. In ...
(Date:11/24/2015)... Nov. 24, 2015 Halozyme Therapeutics, Inc. (NASDAQ: HALO ... New York on Wednesday, December 2 at ... , president and CEO, will provide a corporate overview. ... at 1:00 p.m. ET/10:00 a.m. PT . ... will provide a corporate overview. --> th Annual ...
(Date:11/24/2015)... 2015 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ:  AEZS) (TSX: AEZ) ... of the Toronto Stock Exchange, confirms that as of ... corporate developments that would cause the recent movements in ... --> About Aeterna Zentaris Inc. ... Aeterna Zentaris is a specialty biopharmaceutical company engaged ...
Breaking Biology Technology:
(Date:11/10/2015)... LONDON , Nov. 10, 2015 /PRNewswire/ ... segmented on the basis of product, type, ... segments included in this report are consumables, ... this report are safety biomarkers, efficacy biomarkers, ... in this report are diagnostics development, drug ...
(Date:11/9/2015)...  Synaptics Inc. (NASDAQ: SYNA ), the leading ... into the automotive market with a comprehensive and dedicated ... consumer electronics human interface innovation. Synaptics, industry-leading touch controllers, ... automotive industry and will be implemented in numerous locations ... , Japan , and ...
(Date:10/29/2015)... , Oct. 29, 2015   MedNet Solutions , ... entire spectrum of clinical research, is pleased to announce ... Tech Association (MHTA) as one of only three finalists ... "Software – Small and Growing" category. The Tekne Awards honor ... have shown superior technology innovation and leadership. ...
Breaking Biology News(10 mins):